secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001193125-25-230906
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista appoints Bilal Arif as COO and Linea Aspesi as Chief People Officer
----------------------------------------------------------------------------

- Bilal Arif appointed COO effective Oct 6, 2025; base salary $520k, annual bonus target 40%, option grant of 100,000 shares.
- Linea Aspesi appointed Chief People Officer; also receives inducement option grant of 100,000 shares.
- Both options vest over 4 years: 1/4th on 1-year anniversary, then monthly vesting.
- Appointments support global launch of EKTERLY for hereditary angioedema.
- Arif was EVP at Sarepta Therapeutics; Aspesi was Chief Admin Officer at Editas Medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525230906/0001193125-25-230906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525230906/d42627d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-230906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer